Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Immunexpress Awarded Grant to Bring Sepsis MDx Assay to Market

Published: Wednesday, February 19, 2014
Last Updated: Wednesday, February 19, 2014
Bookmark and Share
Immunexpress receives Early Stage Commercialisation support from Australian Government to further develop SeptiCyte®PLUS.

Immunexpress Group announce it has received Early Stage Commercialisation support through Commercialisation Australia, an initiative of the Australian Government. The AUD $982,707 grant will support the company’s AUD 2.2 million project, intended to bring the Immunexpress innovative whole blood qRT-PCR diagnostic assay (SeptiCyte® PLUS) to market. SeptiCyte® PLUS is designed to diagnose sepsis accurately within a clinically relevant timeframe.

“This is an important step forward in the development of SeptiCyte® PLUS and our efforts to bring novel sepsis assays to health care centers and patients around the world,” said Dr Roslyn Brandon, President and Chief Executive Officer, Immunexpress. “Based on the results to date, SeptiCyte® PLUS has the potential to make an important impact on the health care community and improve patient outcomes by allowing for earlier diagnosis and targeted antimicrobial treatment within a clinically relevant time frame of under three hours.“

The grant funding, along with existing cash resources, will be used to develop the SeptiCyte® PLUS prototype through to a Laboratory Developed Test (LDT), and make it available to hospital labs at two large health systems in the U.S. along with one major academic hospital in Germany. The prospective data collected through these centers is expected to inform the regulatory pathway and future medical device application for SeptiCyte® PLUS in the U.S.

New technologies that allow for the earlier detection and personalized management of people with, or at risk of, sepsis could significantly reduce the financial burden on health care systems worldwide through reduced patient mortality and morbidity; reduced stays in hospital and intensive care units (ICUs); more targeted use of antibiotics and anti-inflammatories; and reduced antimicrobial resistance.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Immunexpress Releases Key Performance Data on SeptiCyte®
Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, have announced the publication of the discovery and validation of the SeptiCyte® Lab test for sepsis.
Friday, December 11, 2015
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Transgenomic, Precipio Diagnostics Merger
Merger will creates a robust diagnostic platform focused on improving accuracy of cancer diagnoses.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
Analysing 10,000 Cells Simultaneously
New techniquethat traps 10,000 cells on a single chip has potential for cancer screening for individuals.
Genetic Tug of War Before Cells Decide Fate
Researchers report that as developing blood cells are triggered by genetic signals firing on and off, a 'tug of war' occurs.
$1M NIH Grant to Refine PCR Based Cancer Test
Researchers at Cornell University, Weill Cornell Medicine, the University of California, San Francisco, and the Infectious Diseases Institute in Kampala, Uganda, recieve a four-year, $1 million grant to hone technology for a quick, in-the-field diagnosis of Kaposi's sarcoma — a cancer frequently related to HIV infections.
Linkage Biosciences Awarded NHS Contract
Comapny announces that it has been awarded a four-year contract by NHS Blood and Transplant (NHSBT) in the UK for implementation of the LinkSeq™ Real-Time PCR HLA typing product.
Understanding Tumor Evolution
Study provides insight into tumor evolution; may point to improved diagnosis and treatment.
Frankfurter Fraud: Finding Out What’s In Your Hot Dog
Scientists have developed a technique to test the meat content of Frankfurters.
How Cloud Connectivity Can Combat the Reproducibility Crisis
This infographic explains the reproducibility crisis, and how cloud connectivity can help overcome this problem.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos